Dalbavancin
| File:Dalbavancin.png | |
| Clinical data | |
|---|---|
| Routes of administration | Intravenous |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C88H100Cl2N10O28 |
| Molar mass | 1755.634 |
|
WikiDoc Resources for Dalbavancin |
|
Articles |
|---|
|
Most recent articles on Dalbavancin Most cited articles on Dalbavancin |
|
Media |
|
Powerpoint slides on Dalbavancin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dalbavancin at Clinical Trials.gov Clinical Trials on Dalbavancin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dalbavancin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dalbavancin Discussion groups on Dalbavancin Patient Handouts on Dalbavancin Directions to Hospitals Treating Dalbavancin Risk calculators and risk factors for Dalbavancin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dalbavancin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Dalbavancin, a novel second-generation lipoglycopeptide agent, belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with MRSA.[1]
It possesses in vitro activity against a variety of gram-positive pathogens[2][3] including MRSA and MRSE. [4]It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.[5]
References and notes
- ↑ Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
- ↑ Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMID 17362476.
- ↑ Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci. 21 (1): 78–88. PMID 18166524.
- ↑ Dalbavancin: A Novel Lipoglycopeptide Antibacterial
- ↑ UPDATE 1-Pfizer says US FDA wants more data on antibiotic
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Glycopeptide antibiotics